首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi

市場調查報告書

商品編碼

1660964

RNA 干擾藥物傳遞市場報告（按應用、技術和地區）2025 年至 2033 年

RNA Interference Drug Delivery Market Report by Application, Technology, and Region 2025-2033

出版日期: 2025年02月10日 | 出版商:

IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2024 年全球 RNA 干擾 (RNAi) 藥物輸送市場規模達到 998 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 4,661 億美元，2025-2033 年期間的成長率 (CAGR) 為 17.75%。

核糖核酸干擾（RNAi）藥物傳遞是一種監測基因表現或突變的治療方案。 RNAi 藥物輸送通常透過靜脈、皮內和腹膜內注射和局部輸送方法進行。它涉及奈米顆粒、肺部、核酸和適體藥物傳輸技術。這些技術也用於分析真核生物的基因功能和開發治療性基因沉默解決方案。因此，RNAi藥物傳遞廣泛用於治療傳染病、慢性代謝紊亂、心血管疾病、神經疾病、泌尿疾病、腫瘤疾病和眼科疾病。

全球癌症和心血管疾病（CVD）等慢性疾病和遺傳疾病的發生率不斷上升，這是推動市場成長的關鍵因素之一。此外，老年人口的增加使人們更容易患上此類疾病，這也推動了市場的成長。同時，隨著冠狀病毒病（COVID-19）繼續在全球蔓延，對 RNAi 藥物傳遞技術的需求顯著增加。標靶遞送方法，例如適體藥物遞送系統，在抗病毒藥物的給藥方面獲得了巨大的吸引力，因為它們是由可以抑制病毒抗原表達的小干擾 RNA (siRNA) 誘導的。此外，各種技術進步，如創新合成運載載體和生物載體的開發，預計將推動市場成長。奈米載體，包括 siRNA 或微小 RNA（miRNA），對於開發個人化藥物和識別改變的細胞分子和代謝物至關重要。其他因素，包括奈米技術和分子診斷領域的廣泛研究和開發 (R&D) 活動，以及醫療保健基礎設施的全面改善，預計將進一步推動市場發展。

本報告回答的關鍵問題：

全球 RNA 干擾（RNAi）藥物輸送市場迄今表現如何，未來幾年將如何表現？
COVID-19 對全球 RNA 干擾 (RNAi) 藥物輸送市場有何影響？
主要的區域市場有哪些？
根據應用，市場區隔是怎樣的？
基於科技的市場分化是怎樣的？
該產業的價值鏈分為哪些階段？
該行業的關鍵促進因素和挑戰是什麼？
全球 RNA 干擾（RNAi）藥物輸送市場的結構是怎樣的？
產業的競爭程度如何？

傳染病
- 市場趨勢
- 市場預測
心臟病學
- 市場趨勢
- 市場預測
腫瘤學
- 市場趨勢
- 市場預測
神經病學
- 市場趨勢
- 市場預測
眼科
- 市場趨勢
- 市場預測
泌尿科
- 市場趨勢
- 市場預測
代謝紊亂
- 市場趨勢
- 市場預測
其他
- 市場趨勢
- 市場預測

第7章：市場區隔：依技術

奈米顆粒藥物輸送
- 市場趨勢
- 市場預測
肺部藥物輸送
- 市場趨勢
- 市場預測
核酸藥物輸送
- 市場趨勢
- 市場預測
適體藥物遞送
- 市場趨勢
- 市場預測

第 8 章：市場區隔：按地區

北美洲
- 美國
- 加拿大
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 其他
歐洲
- 德國
- 法國
- 英國
- 義大利
- 西班牙
- 俄羅斯
- 其他
拉丁美洲
- 巴西
- 墨西哥
- 其他
中東和非洲
- 市場趨勢
- 市場區隔：依國家
- 市場預測

第 9 章：SWOT 分析

概述
優勢
弱點
機會
威脅

第 10 章：價值鏈分析

第 11 章：波特五力分析

概述
買家的議價能力
供應商的議價能力
競爭程度
新進入者的威脅
替代品的威脅

第 12 章：價格分析

第 13 章：競爭格局

市場結構
關鍵參與者
關鍵參與者簡介
- Alnylam Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- CureVac AG
- Dicerna Pharmaceuticals Inc.
- Gradalis Inc.
- Ionis Pharmaceuticals Inc
- Merck & Co. Inc.
- Moderna Inc.
- Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
- Silence Therapeutics Plc
- Sirnaomics Inc.

簡介目錄圖表

Product Code: SR112025A2758

The global RNA interference (RNAi) drug delivery market size reached USD 99.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 466.1 Billion by 2033, exhibiting a growth rate (CAGR) of 17.75% during 2025-2033.

Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Application:

Infectious Disease
Cardiology
Oncology
Neurology
Ophthalmology
Urology
Metabolic Disorders
Others

Breakup by Technology:

Nanoparticle Drug Delivery
Pulmonary Drug Delivery
Nucleic Acid Drug Delivery
Aptamer Drug Delivery

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc, and Sirnaomics Inc.

Key Questions Answered in This Report:

How has the global RNA interference (RNAi) drug delivery market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global RNA interference (RNAi) drug delivery market?
What are the key regional markets?
What is the breakup of the market based on the application?
What is the breakup of the market based on the technology?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global RNA interference (RNAi) drug delivery market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global RNA Interference (RNAi) Drug Delivery Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Application

6.1 Infectious Disease
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Cardiology
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Oncology
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Neurology
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Ophthalmology
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Urology
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
6.7 Metabolic Disorders
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
6.8 Others
- 6.8.1 Market Trends
- 6.8.2 Market Forecast

7 Market Breakup by Technology

7.1 Nanoparticle Drug Delivery
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Pulmonary Drug Delivery
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Nucleic Acid Drug Delivery
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Aptamer Drug Delivery
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Region

8.1 North America
- 8.1.1 United States
  - 8.1.1.1 Market Trends
  - 8.1.1.2 Market Forecast
- 8.1.2 Canada
  - 8.1.2.1 Market Trends
  - 8.1.2.2 Market Forecast
8.2 Asia Pacific
- 8.2.1 China
  - 8.2.1.1 Market Trends
  - 8.2.1.2 Market Forecast
- 8.2.2 Japan
  - 8.2.2.1 Market Trends
  - 8.2.2.2 Market Forecast
- 8.2.3 India
  - 8.2.3.1 Market Trends
  - 8.2.3.2 Market Forecast
- 8.2.4 South Korea
  - 8.2.4.1 Market Trends
  - 8.2.4.2 Market Forecast
- 8.2.5 Australia
  - 8.2.5.1 Market Trends
  - 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
  - 8.2.6.1 Market Trends
  - 8.2.6.2 Market Forecast
- 8.2.7 Others
  - 8.2.7.1 Market Trends
  - 8.2.7.2 Market Forecast
8.3 Europe
- 8.3.1 Germany
  - 8.3.1.1 Market Trends
  - 8.3.1.2 Market Forecast
- 8.3.2 France
  - 8.3.2.1 Market Trends
  - 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
  - 8.3.3.1 Market Trends
  - 8.3.3.2 Market Forecast
- 8.3.4 Italy
  - 8.3.4.1 Market Trends
  - 8.3.4.2 Market Forecast
- 8.3.5 Spain
  - 8.3.5.1 Market Trends
  - 8.3.5.2 Market Forecast
- 8.3.6 Russia
  - 8.3.6.1 Market Trends
  - 8.3.6.2 Market Forecast
- 8.3.7 Others
  - 8.3.7.1 Market Trends
  - 8.3.7.2 Market Forecast
8.4 Latin America
- 8.4.1 Brazil
  - 8.4.1.1 Market Trends
  - 8.4.1.2 Market Forecast
- 8.4.2 Mexico
  - 8.4.2.1 Market Trends
  - 8.4.2.2 Market Forecast
- 8.4.3 Others
  - 8.4.3.1 Market Trends
  - 8.4.3.2 Market Forecast
8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast

9 SWOT Analysis

9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- 13.3.1 Alnylam Pharmaceuticals Inc.
  - 13.3.1.1 Company Overview
  - 13.3.1.2 Product Portfolio
  - 13.3.1.3 Financials
  - 13.3.1.4 SWOT Analysis
- 13.3.2 Arrowhead Pharmaceuticals Inc.
  - 13.3.2.1 Company Overview
  - 13.3.2.2 Product Portfolio
  - 13.3.2.3 Financials
- 13.3.3 CureVac AG
  - 13.3.3.1 Company Overview
  - 13.3.3.2 Product Portfolio
  - 13.3.3.3 Financials
- 13.3.4 Dicerna Pharmaceuticals Inc.
  - 13.3.4.1 Company Overview
  - 13.3.4.2 Product Portfolio
  - 13.3.4.3 Financials
- 13.3.5 Gradalis Inc.
  - 13.3.5.1 Company Overview
  - 13.3.5.2 Product Portfolio
- 13.3.6 Ionis Pharmaceuticals Inc
  - 13.3.6.1 Company Overview
  - 13.3.6.2 Product Portfolio
  - 13.3.6.3 Financials
  - 13.3.6.4 SWOT Analysis
- 13.3.7 Merck & Co. Inc.
  - 13.3.7.1 Company Overview
  - 13.3.7.2 Product Portfolio
  - 13.3.7.3 Financials
  - 13.3.7.4 SWOT Analysis
- 13.3.8 Moderna Inc.
  - 13.3.8.1 Company Overview
  - 13.3.8.2 Product Portfolio
  - 13.3.8.3 Financials
- 13.3.9 Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
  - 13.3.9.1 Company Overview
  - 13.3.9.2 Product Portfolio
- 13.3.10 Silence Therapeutics Plc
  - 13.3.10.1 Company Overview
  - 13.3.10.2 Product Portfolio
  - 13.3.10.3 Financials
- 13.3.11 Sirnaomics Inc.
  - 13.3.11.1 Company Overview
  - 13.3.11.2 Product Portfolio

簡介目錄圖表

List of Figures

Figure 1: Global: RNA Interference (RNAi) Drug Delivery Market: Major Drivers and Challenges
Figure 2: Global: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Application (in %), 2024
Figure 4: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Technology (in %), 2024
Figure 5: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Region (in %), 2024
Figure 6: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 7: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market: Sales Value (in Million USD), 2019 & 2024
Figure 8: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 9: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: North America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: North America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: United States: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: United States: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Canada: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Canada: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: China: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: China: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Japan: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Japan: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: India: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: India: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: South Korea: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: South Korea: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: Australia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: Australia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Indonesia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Indonesia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: Europe: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: Europe: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: Germany: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: Germany: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: France: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: France: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: United Kingdom: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: United Kingdom: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: Italy: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: Italy: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Spain: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Spain: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: Russia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: Russia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Latin America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Latin America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Brazil: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Brazil: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: Mexico: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: Mexico: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million USD), 2019 & 2024
Figure 78: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: Global: RNA Interference (RNAi) Drug Delivery Industry: SWOT Analysis
Figure 80: Global: RNA Interference (RNAi) Drug Delivery Industry: Value Chain Analysis
Figure 81: Global: RNA Interference (RNAi) Drug Delivery Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: RNA Interference (RNAi) Drug Delivery Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Application (in Million USD), 2025-2033
Table 3: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Technology (in Million USD), 2025-2033
Table 4: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 5: Global: RNA Interference (RNAi) Drug Delivery Market Structure
Table 6: Global: RNA Interference (RNAi) Drug Delivery Market: Key Players

02-2729-4219

+886-2-2729-4219